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ABSTRACT (Maximum 300; current count 380 words) 
BACKGROUND 
Treatments for small-cell lung cancer (SCLC) after failure of platinum-based chemotherapy are limited. We 
assessed safety and activity of nivolumab and nivolumab plus ipilimumab in patients with SCLC who progressed 
after one or more prior regimens. 
METHODS 
The SCLC cohort of this phase 1/2 international multiarm open-label trial was conducted at 23 sites. Eligible 
patients were 18 years of age or older, had limited or extensive-stage SCLC, and had disease progression after at 
least one prior platinum-containing regimen. Patients received nivolumab (3 mg/kg) every 2 weeks, or nivolumab 
plus ipilimumab (1 mg/kg plus 1 mg/kg, 1 mg/kg plus 3 mg/kg, or 3 mg/kg plus 1 mg/kg, respectively) every 3 
weeks for four cycles, followed by nivolumab 3 mg/kg every 2 weeks. Patients were either assigned to nivolumab 
monotherapy or assessed in a dose escalating safety phase for the nivolumab/ipilimumab combination beginning at 
nivolumab-1/ipilimumab-1. Depending on tolerability, patients were then assigned to nivolumab-1/ipilimumab-3 or 
nivolumab-3/ipilimumab-1. The primary endpoint was objective response rate (ORR). All analyses included patients 
who were enrolled at least 90 days prior to database lock. This trial is ongoing; an interim analysis is reported here. 
This study is registered with ClinicalTrials.gov, number NCT01928394. 
FINDINGS 
Between Nov 18, 2013 and July 28, 2015, 216 patients were enrolled and treated (n=98, nivolumab-3; n=3, 
nivolumab-1/ipilimumab-1; n=61, nivolumab-1/ipilimumab-3; n=54, nivolumab-3/ipilimumab-1). ORRs were 10% 
(10/98), 23% (14/61), and 19% (10/54) for patients receiving nivolumab-3, nivolumab-1/ipilimumab-3, and 
nivolumab-3/ipilimumab-1, respectively. In the nivolumab-3, nivolumab-1/ipilimumab-3, and nivolumab-
3/ipilimumab-1 cohorts, respectively, 13 (13%), 18 (30%), and 10 (19%) patients reported grade 3 or 4 treatment-
related adverse events; across arms, the most commonly reported grade 3 or 4 treatment-related AEs were increased 
lipase (5 [2%]), diarrhea (4 [2%]), dyspnea (3 [1%]), and pneumonitis (3 [1%]), In the nivolumab-3, nivolumab-
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1/ipilimumab-3, and nivolumab-3/ipilimumab-1 cohorts, respectively, four (4%), seven (11%), and four (7%) 
patients discontinued due to treatment-related adverse events. One patient who received nivolumab-1/ipilimumab-3 
died from treatment-related myaesthenia gravis. 
INTERPRETATION 
Nivolumab monotherapy and nivolumab plus ipilimumab showed antitumour activity with durable responses and 
manageable safety profiles in previously treated patients with SCLC. These data suggest a potential new treatment 
approach for a population of patients with limited treatment options and support the evaluation of nivolumab and 
nivolumab plus ipilimumab in phase 3 randomised controlled trials in SCLC. 
FUNDING 
Bristol-Myers Squibb 
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INTRODUCTION 
Small-cell lung cancer (SCLC), which accounts for approximately 14% of all lung cancers, is strongly associated 
with tobacco use and has high mutation rates without known oncogenic drivers.
1,2
 Most patients present with 
extensive-stage disease characterised by widespread metastases and poor survival.
2
 Although 35% to 86% of 
patients respond to first-line chemotherapy, disease progresses rapidly, and outcomes with second-line treatment are 
poor.
3-6 
 
Standard first-line chemotherapy for SCLC is a platinum-etoposide doublet, with topotecan as second-line therapy in 
the United States (US) and European Union (EU)
1
 and amrubicin as second-line therapy in Japan.
7
 Though response 
rates with topotecan are 23% and 9% for platinum-sensitive and platinum-resistant/refractory patients, respectively, 
they are not durable.
8
 
Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint–inhibitor antibody, significantly 
improved overall survival and had a favourable safety profile compared with docetaxel in two phase 3 studies of 
patients with non-SCLC (NSCLC) who progressed after first-line platinum-based doublet chemotherapy,
9,10
 leading 
to its approval in the US for treatment of patients with metastatic NSCLC and in the EU for treatment of patients 
with locally advanced or metastatic squamous NSCLC.
11
 Ipilimumab, a fully human IgG1 cytotoxic T-lymphocyte 
antigen 4 (CTLA-4) immune-checkpoint inhibitor, significantly improved overall survival in two phase 3 studies in 
patients with advanced melanoma, leading to approval in the US and the EU for this indication.
12,13
 
Preclinical data indicate that the combination of PD-1 and CTLA-4 receptor blockade may improve antitumour 
activity,
14 
and the combination of nivolumab plus ipilimumab has demonstrated deep and durable responses in 
several tumour types.
15-17 
The combination of nivolumab plus ipilimumab is approved in the US for treatment of 
advanced melanoma. Based on the efficacy of combination treatment in melanoma, CheckMate 032 was designed as 
a phase 1/2 trial to investigate the activity and safety of nivolumab as monotherapy or in combination with 
ipilimumab in several advanced or metastatic tumour types. The evaluation of nivolumab monotherapy and the 
combination of nivolumab and ipilimumab in patients with advanced or metastatic solid tumours for which no 
standard of care in advanced lines of treatment exists will potentially generate evidence of antitumour activity as a 
basis for further clinical development in these tumour types. Here, we report activity, safety, and biomarker analyses 
for the SCLC cohort. 
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METHODS 
STUDY DESIGN AND PARTICIPANTS 
This was an international phase 1/2, two-stage, open-label multiarm trial. Patients with SCLC were enrolled at 23 
sites in six countries (Finland, Germany, Italy, Spain, UK, and US) (page 18, appendix). Eligible patients had 
histologically or cytologically-confirmed limited or extensive-stage SCLC, with progressive disease after at least 
one platinum-based chemotherapy regimen. Patients with platinum-sensitive or platinum-resistant disease (relapse ≥ 
or <90 days after, or during, chemotherapy, respectively) were eligible regardless of programmed death-ligand 1 
(PD-L1) expression. Patients were ≥18 years of age, with an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 or 1 (0 to 5 scale: 0, no symptoms; 1, mild; higher numbers, greater tumour-related 
disability) and had adequate organ function. Patients were required to have measurable disease per the Response 
Evaluation Criteria in Solid Tumors (RECIST), version 1·1,
18
 and baseline tumour biopsy or archival tumour 
material available for biomarker analyses. Tumour material was acceptable from biopsies performed before the 
screening period if the biopsy was done up to 3 months prior to start of treatment and no other systemic cancer 
therapy was administered in that time. Baseline laboratory tests required to assess eligibility included white blood 
cell counts, neutrophils, platelets, haemoglobin, serum creatinine, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), total bilirubin, albumin, lipase, and amylase. Key exclusion criteria included active brain or 
leptomeningeal metastases, a history of autoimmune disease (except for vitiligo, type I diabetes mellitus, residual 
hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, or conditions not expected to 
recur in the absence of an external trigger), the need for immunosuppressive doses of systemic corticosteroids (>10 
mg per day prednisone equivalents) 2 weeks prior to study drug administration, and prior treatment with antibodies 
that modulate T-cell function or checkpoint pathways. Patients were also excluded if they tested positive for 
hepatitis B virus or human immunodeficiency virus, and had unresolved toxicities from prior anticancer therapies. 
Patient selection was not based on estimated survival. Median survival for patients with relapsed SCLC has been 
reported as approximately 3·5–12 months.4 
The study protocol was approved by an institutional review board or ethics committee at each participating centre. 
The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, as 
defined by the International Conference on Harmonisation. Prior to performing any study-specific procedures, 
written informed consent was obtained from all patients. 
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PROCEDURES 
Considerations for the dosing in the combination cohorts were as follows: the 1 mg/kg nivolumab plus 3 mg/kg 
ipilimumab regimen is the approved dose for the treatment of advanced melanoma;
11,19
 the 3 mg/kg nivolumab plus 
1 mg/kg ipilimumab regimen was chosen to maximize the nivolumab dose based on nivolumab exposure response 
data (1 mg/kg vs 3 mg/kg);
20
 and to ensure that nivolumab plus ipilimumab is tolerable in patients with SCLC, an 
initial dose-escalating safety evaluation step was performed (starting with 1 mg/kg nivolumab plus 1 mg/kg 
ipilimumab). The safety of the 1 mg/kg nivolumab plus 3 mg/kg ipilimumab and the 3 mg/kg nivolumab plus 1 
mg/kg ipilimumab regimens have been previously assessed in studies of other tumour types.
15-17,21,22
 
Patients with SCLC were assigned to one of the following treatment cohorts, nivolumab as monotherapy at 3 mg per 
kilogram of body weight (nivolumab-3) administered intravenously every 2 weeks, orcombination treatment of 
nivolumab plus ipilimumab administered intravenously every 3 weeks for 4 cycles, at dose level 1 (nivolumab 1 
mg/kg + ipilimumab 1 mg/kg [nivolumab-1/ipilimumab-1]), dose level 2 (nivolumab 1 mg/kg + ipilimumab 3 mg/kg 
[nivolumab-1/ipilimumab-3]), or dose level 2b (nivolumab 3 mg/kg + ipilimumab 1 mg/kg [nivolumab-
3/ipilimumab-1]), followed by 3 mg/kg of nivolumab every 2 weeks. To ensure that the planned combination 
regimens would be tolerable in patients with SCLC, an initial dose-escalating safety evaluation for the combination 
arms was conducted. The first dose cohort was level 1. If this was deemed tolerable, then level 2 was initiated. If 
dose level 2 was deemed not tolerable, dose level 2b was investigated. Once the highest dose level for further 
investigation was confirmed in the dose-escalating safety evaluation phase, the combination arms continued 
enrolling patients. Patients on active treatment needed to be followed up for at least 6 weeks after the start of study 
treatment before tolerability of a dose level was determined based on prespecified tolerability assessment criteria. 
However, tolerability beyond 6 weeks was also taken into consideration. For combination treatment, nivolumab was 
administered first (60-minute infusion), followed by ipilimumab (90-minute infusion), as per previous studies 
evaluating nivolumab plus ipilimumab.
21,22
 Patients received open-label treatment until disease progression or 
occurrence of unacceptable toxicity (figure 1). Treatment beyond RECIST, version 1·1-defined progression was 
permitted if the patient was tolerating and benefiting from treatment, based on investigator assessment. Using an 
interactive voice response system, patients were enrolled in one of the four cohorts in a sequential manner, or 
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assigned if more than one cohort was open for enrolment. Patients progressing on nivolumab-3 could cross over to 
combination cohorts. 
No dose reductions or modifications were permitted for nivolumab or ipilimumab. Criteria for dose delays (which 
were required for protocol-defined reasons) and treatment discontinuation are detailed in the appendix.   
Tumour assessments by radiographic imaging were done at baseline, every 6 weeks for the first 24 weeks, and every 
12 weeks thereafter until disease progression (investigator-assessed per RECIST, version 1·1-defined progression) 
or treatment discontinuation. Survival was monitored continuously while patients were on treatment and every 3 
months after treatment discontinuation. Safety was evaluated throughout the study (page 19, appendix), and adverse 
events were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events, 
version 4·0. 
Tumour PD-L1 protein expression was assessed retrospectively in pretreatment (archival or fresh) tumour biopsy 
specimens with the use of a validated, automated immunohistochemical assay (Dako North America, Carpinteria, 
CA, USA) using a rabbit antihuman PD-L1 antibody (clone 28-8, Epitomics Inc, Burlingame, CA, USA).
23
 Tumour 
PD-L1 expression was categorised as positive when staining of tumour-cell membranes (at any intensity) was 
observed at prespecified expression levels of ≥1% or ≥5% of tumour cells in a section that included ≥100 evaluable 
tumour cells. In the initial study protocol, analysis of the specimen was not required in advance of patient 
randomisation; the protocol was later revised and this was made a requirement via a study amendment on August 6, 
2015. 
 
OUTCOMES 
The primary endpoint of this study was the proportion of patients with a confirmed objective response (defined as 
the number of patients with a best overall response of complete response or partial response [as per investigator-
assessed RECIST, version 1·1 criteria] divided by the number of assigned patients). The objective response rate was 
the primary endpoint as the trial objective was to evaluate antitumour activity of nivolumab monotherapy or in 
combination with ipilimumab.   
The secondary endpoints included overall survival, progression-free survival, duration of response, and the rate of 
treatment-related adverse events leading to treatment discontinuation. Overall survival was defined as the time 
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between the date of treatment assignment and the date of death due to any cause. Progression-free survival was 
defined as the time from treatment assignment to the date of the first documented tumour progression, as determined 
by the investigator (per RECIST, version 1·1), or death due to any cause, whichever occurred first. Duration of 
response was defined as the time from a best overall response of partial or complete response until the date 
progressive disease was documented (using RECIST version 1·1) or death due to any cause. The correlation 
between PD-L1 expression by tumour cells and antitumour activity was a prespecified exploratory endpoint. 
All activity analyses were performed on the basis of the original treatment assignment, not by crossover status.  
 
STATISTICAL ANALYSIS 
In parallel to the safety evaluation phase for the combination arms (as described in Procedures), enrolment of 
patients followed a Simon two-stage design.
24
 This design was used to test whether nivolumab and/or the 
combination of nivolumab and ipilimumab yields an objective response rate that is of clinical interest in each of the 
tumour types; it also limits the expected number of patients who receive treatment when the true response rate is not 
of clinical value. The two-stage test was conducted independently in each cohort. 
For each cohort, the Simon design requires 18 treated patients for the first stage and calls for termination of a cohort 
at stage 1 if there is less than one responder among the 18 treated patients within the cohort. Otherwise, if two or 
more responders are identified in up to 18 patients in a cohort, additional patients will be assigned, to a total of 40 
treated patients in that cohort. The treatment will be considered of clinical interest if, at the end of the second stage, 
there are eight or greater responders among 40 treated patients in any single cohort.  
Only treatment arms that met an objective response rate threshold proceeded from stage 1 to stage 2. Enrolment in 
stage 2 in a given treatment arm could continue even if the other treatment arm was still in stage 1. 
For stage 2, upon completion of enrolment for the initial 40 patients, additional patients were assigned into the 
nivolumab monotherapy arm and the combination arms up to a total of 100 patients (including those assigned in 
stage 1) in each treatment arm. When nivolumab monotherapy or nivolumab-1/ipilimumab-3 proceeded to stage 2, 
assessment of dose level 2b in stage 2 (nivolumab-3/ipilimumab-1) was initiated. 
The date of the database lock for all activity and safety data was November 6, 2015. All analyses included treated 
patients who were enrolled at least 90 days prior to database lock. 
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Objective response rates were summarised by a binomial response rate and corresponding two-sided 95% exact 
confidence interval (CI) using the Clopper-Pearson method. Progression-free survival and overall survival were 
summarised descriptively using Kaplan-Meier methodology; median values were estimated with two-sided 95% CIs, 
calculated using the Brookmeyer-Crowley method. Only treatment cohorts with more than six patients are 
represented in Kaplan-Meier plots. Patient with less than 12 weeks follow-up were excluded from Kaplan-Meier 
plots. Progression-free survival and overall survival rates were also estimated with two-sided 95% CIs, calculated 
using the Greenwood formula. Duration of response was summarised using the Kaplan-Meier product-limit method. 
For PD-L1 biomarker analysis, best overall response was summarised for each cohort by baseline PD-L1 expression 
and objective response rates, with exact 95% CIs computed using the Clopper-Pearson method. All statistical 
analyses were performed using SAS software (version 9.02).  
This study is registered with ClinicalTrials.gov, number NCT01928394. 
 
 
ROLE OF THE FUNDING SOURCE 
The funder provided the study drug and worked with the investigators to design the study, and to collect, analyse, 
and interpret the data. All authors made the decision to submit the report for publication, and all drafts of the report 
were prepared by the corresponding author with input from coauthors and editorial assistance from professional 
medical writers, funded by the sponsor. Raw data were made accessible to the authors and professional medical 
writers.  
 
RESULTS  
PATIENTS AND TREATMENT 
From November 18, 2013, through July 28, 2015, 216 patients with SCLC were enrolled and treated, including 98 
patients in the nivolumab-3 cohort. While the nivolumab-1/ipilimumab-3 and nivolumab-3/ipilimumab-1 regimens 
were expected to be tolerable based on prior studies in other tumour types,
15,16,21,22
 an initial safety evaluation of 
nivolumab-1/ipilimumab-1 was conducted. Patients in this first combination–dose-level cohort, nivolumab-
1/ipilimumab-1 (n=3), tolerated the combination well, allowing for further escalation and expansion in the other two 
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combination cohorts: nivolumab-1/ipilimumab-3 (n=61) and nivolumab-3/ipilimumab-1 (n=54) (figure 1). Data on 
the three patients who remained in the nivolumab-1/ipilimumab-1 cohort are provided as supplementary materials 
(pages 20–22, appendix). At database lock, the median follow-up for patients continuing in the study was 198·5 
days (interquartile range [IQR], 163·0–464·0), 361·0 days (IQR, 273·0–470·0), and 260·5 days (IQR, 248·0–288·0) 
in the nivolumab-3, nivolumab-1/ipilimumab-3, and nivolumab-3/ipilimumab-1 cohorts, respectively (page 23, 
appendix). In the nivolumab-3, nivolumab-1/ipilimumab-3, and nivolumab-3/ipilimumab-1 cohorts, 59%, 48%, and 
57% of patients, respectively, had been treated with two or more previous regimens; 31%, 38%, and 39%, 
respectively, had platinum-resistant disease (table 1). 
Patients received a median of 3.5 infusions of nivolumab (IQR, 2·0–6·0) in the nivolumab-3 cohort, three infusions 
each of nivolumab (IQR, 2·0–14·0) and ipilimumab (IQR, 2·0–4·0) in the nivolumab-1/ipilimumab-3 cohort, and 
two infusions each of nivolumab (IQR, 2·0–6·0) and ipilimumab (IQR, 2·0–4·0) in the nivolumab-3/ipilimumab-1 
cohort (page 23, appendix). At the time of analysis, 79%, 69%, and 80% of patients in the nivolumab-3, nivolumab-
1/ipilimumab-3, and nivolumab-3/ipilimumab-1 cohorts, respectively, had discontinued treatment; the most common 
cause was disease progression (page 23, appendix).  
 
CLINICAL ACTIVITY 
The rate of confirmed objective response was 10% (10/98, 95% CI, 5–18) with nivolumab-3, 23% (14/61, 95% CI, 
13–36) with nivolumab-1/ipilimumab-3, and 19% (10/54, 95% CI, 9–31) with nivolumab-3/ipilimumab-1 (table 2; 
figures 2A, 2B, and 2C). The median duration of response was not reached (95% CI, 4·4–not reached) with 
nivolumab-3, 7·7 months (95% CI, 4·0–not reached) with nivolumab-1/ipilimumab-3, and 4·4 months (95% CI, 
3·7–not reached) with nivolumab-3/ipilimumab-1. Median time to response was 2·0 months (IQR, 1·3–2·8), 2·1 
months (IQR, 1·4–2·8), and 1·4 months (IQR, 1·3–2·7) in the nivolumab-3, nivolumab-1/ipilimumab-3, and 
nivolumab-3/ipilimumab-1 cohorts, respectively (table 2). At the time of database lock, eight of 10, seven of 14, and 
seven of 10 responses were ongoing in the nivolumab-3, nivolumab-1/ipilimumab-3 and nivolumab-3/ipilimumab-1 
arms, respectively. Thirty, 15, and 6 patients in the nivolumab-3, nivolumab-1/ipilimumab-3, and nivolumab-
3/ipilimumab-1 cohorts, respectively, continued treatment beyond progression. 
In the nivolumab-3, nivolumab-1/ipilimumab-3, and nivolumab-3/ipilimumab-1 cohorts, median overall survival 
was 4·7 months (95% CI, 3·0–9·3), 7·7 months (95% CI, 3·6–not reached), and 7·2 months (95% CI, 3·7–not 
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reached), respectively, and median progression-free survival was 1·4 months (95% CI, 1·4–1·9), 2·6 months (95% 
CI, 1·4 –4·1), and 1·4 months (95% CI, 1·3 –2·2), respectively. At the time of analysis, 48/98 (49%), 30/61 (49%), 
and 25/54 (46%) patients had died, and 76/98 (78%), 44/61 (72%) and 42/54 (78%) experienced disease progression 
or death in the nivolumab-3, nivolumab-1/ipilimumab-3, and nivolumab-3/ipilimumab-1 cohorts, respectively. One-
year overall survival rates were 31% (95% CI, 19–45) and 42% (95% CI, 28–56) for the nivolumab-3 and 
nivolumab-1/ipilimumab-3 cohorts, respectively (figure 3A), whereas 1-year progression-free survival rates were 
11% and 19%, respectively (figure 3B). The nivolumab-3/ipilimumab-1 cohort had not met the 1-year milestone at 
the time of database lock. 
 
SUBGROUP ANALYSES 
Objective response rates were 10% (4/40), 28% (9/32), and 22% (5/23) for the nivolumab-3, nivolumab-
1/ipilimumab-3, and nivolumab-3/ipilimumab-1 cohort patients with one prior line of therapy, respectively, and 10% 
(6/58), 17% (5/29), and 16% (5/31), respectively, for patients with two or more prior therapies (page 24, appendix). 
Median overall survival and progression-free survival were not substantially different for patients with one versus 
two or more prior treatments, with the possible exception of longer progression-free survival in patients with one 
prior therapy receiving nivolumab-1/ipilimumab-3 (pages 4–9, appendix). Of nine patients who crossed over from 
the nivolumab monotherapy arm to the combination cohorts (one to nivolumab-1/ipilimumab-3 and eight to 
nivolumab-3/ipilimumab-1), eight patients experienced disease progression; one patient in the nivolumab-
3/ipilimumab-1 arm withdrew consent, and response could not be determined. 
In patients treated with a platinum agent in first line, objective response rates of 11% (6/55), 28% (7/25), and 19% 
(4/21) in patients with platinum-sensitive disease and of 10% (3/30), 17% (4/23), and 10% (2/21) in patients with 
platinum-resistant disease were reported for the nivolumab-3, nivolumab-1/ipilimumab-3, and nivolumab-
3/ipilimumab-1 cohorts, respectively (pages 10–13 and page 24, appendix). Among patients with platinum-sensitive 
disease, 4% (2/55) and 8% (2/25) of patients in the nivolumab-3 and nivolumab-1/ipilimumab-3 arms, respectively, 
received subsequent platinum-based cancer therapy. No patients with platinum-sensitive disease in the nivolumab-
3/ipilimumab-1 arm received subsequent platinum-based cancer therapy.   
Overall, PD-L1 expression was evaluable in 146 patient samples (69%), of which 39 (27%) were provided as fresh 
biopsies and 107 (73%) were archived specimens. Of the evaluable samples, 24 (16%) had PD-L1 expression ≥1%, 
13 
 
and seven (5%) had PD-L1 expression ≥5% (table 1). Tumour responses occurred in patients with ≥1% and in 
patients with <1% tumour PD-L1 expression (pages 14–17, appendix).   
Analysis of antitumour activity by levels of PD-L1 expression was a prespecified exploratory endpoint; all other 
subgroup analyses were performed post-hoc.   
 
SAFETY 
The rates of grade 3 or 4 treatment-related adverse events were 13% (13/98), 30% (18/61), and 19% (10/54), 
respectively, in the nivolumab-3, nivolumab-1/ipilimumab-3, and nivolumab-3/ipilimumab-1 cohorts; four (4%), 
seven (11%), and four (7%) patients, respectively, discontinued study because of treatment-related adverse events 
(table 3 and page 23, appendix). One patient in the nivolumab-1/ipilimumab-3 cohort died from treatment-related 
myaesthenia gravis (page 3, appendix).
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Two patients had grade 2 limbic encephalitis: one in the nivolumab-3 cohort (reported as not treatment-related by 
investigator) and one in the nivolumab-1/ipilimumab-3 cohort (reported as treatment-related by investigator); both 
events resolved with immunosuppressive treatment. One patient in the nivolumab-3 cohort had grade 4 limbic 
encephalitis (reported as treatment-related by investigator) that did not resolve with intravenous immunoglobulin 
and corticosteroid treatment.  
Pneumonitis occurred in nine patients (4%, three patients in each cohort), leading to treatment discontinuation in 
five patients; one patient in each cohort had grade 3 or 4 pneumonitis. Treatment-related grade 3 or 4 elevations in 
liver function tests resulted in treatment discontinuation for two patients in the nivolumab-3 cohort (page 29, 
appendix). One patient who crossed over from nivolumab-3 to nivolumab-1/ipilimumab-3 experienced treatment-
related grade 3 elevations in alanine aminotransferase levels (page 3, appendix). Five patients in the nivolumab-
1/ipilimumab-3 cohort had grade 3 or 4 asymptomatic lipase elevations without clinical signs of pancreatitis (table 
3).  
 
DISCUSSION  
Our findings show that nivolumab monotherapy or in combination with ipilimumab provide clinically meaningful 
activity and an acceptable safety profile for patients with limited or extensive-stage SCLC and disease progression 
14 
 
after at least one prior regimen. The prognosis for patients with progression after prior treatment with platinum-
based chemotherapy is poor. Patients with advanced SCLC frequently respond to first-line therapy; however, 
recurrence is inevitable, and effective options at the time of progression and in patients with platinum-resistant 
disease are limited. Patients with extensive-stage SCLC have a 2-year survival rate of <5%.
2,4,7
 
Our trial enrolled a heterogeneous patient population with platinum-sensitive or platinum-resistant disease and a 
range of prior lines of therapy, making comparisons to second-line trials difficult. Responses and stable disease were 
seen in all treatment cohorts. Although the numbers of patients in subgroups were small, preliminary analysis 
showed similar response rates between platinum-sensitive and platinum-resistant subgroups, and similar activity in 
patients with one prior regimen and those with two or more prior regimens. Across treatment groups, responses were 
durable: 16 patients had responses lasting longer than 6 months (range 6·9 to 17·1+ months), including 13 patients 
with ongoing responses (range 7·0+ to 17·1+ months) at the time of database lock.  
One phase 2 study evaluated temozolomide in a similar population of patients with disease progression after one or 
two prior chemotherapy regimens. While the objective response rates were similar to those demonstrated in our 
study—23% (11/48) in patients with platinum-sensitive disease and 13% (2/16) in patients with platinum-refractory 
disease—the median duration of response to temozolomide was lower: 3·5 months (range, 1·4–14·7 months) for all 
treated patients.
26
 A newer agent, Rova-T, a DLL3 targeted antibody drug conjugate, demonstrated anti-tumour 
activity and manageable toxicity in a phase 1 study of patients with SCLC and progression after one or two previous 
lines of therapy.
27
 The objective response rate was 44% (7/16) in patients positive for the DLL3 biomarker treated at 
the maximum tolerated doses.   
Limitations of our study include that the study cohorts were not randomised, and the study was not powered for 
formal comparisons across cohorts. Baseline characteristics were generally similar across the cohorts, and although 
the combination cohorts showed similar response rates, responses appeared to be deeper with the nivolumab-
1/ipilimumab-3 regimen. This dosing regimen has also been shown to be efficacious in previously untreated 
melanoma.
16
 
The activity of nivolumab as monotherapy or combined with ipilimumab as observed in patients irrespective of 
platinum sensitivity or line of therapy is an important aspect differentiating immune-checkpoint inhibitors from 
topotecan or amrubicin in SCLC. Response rates to topotecan depend on chemosensitivity, driven by tumour 
resistance mutations.
7,8
 In contrast, the genomically unstable nature of SCLC
2
 may make it sensitive to immune-
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checkpoint blockade via induction or restoration of a tumour antigen-driven immune response. As few lymphocytes 
are observed in SCLC tumours,
28
 one hypothesis is that there is a greater need to target the lymphoid compartment 
with CTLA-4 inhibition in addition to PD-1 inhibition to maximise the treatment effect.
29
 
Some studies have shown increased activity of PD-1 blockade in patients with PD-L1–expressing NSCLC. However, 
data, including that from this study, suggest that there is a lower prevalence of PD-L1 expression in SCLC versus 
NSCLC.
9,10,30
 A trial of pembrolizumab, a PD-1 immune checkpoint inhibitor, reported an initial response rate of 
25% (4/16) and durable responses in patients with PD-L1–positive extensive-stage SCLC.30 In our study, objective 
responses were observed in patients regardless of PD-L1 expression, including deep tumour responses in patients 
with PD-L1 tumour expression <1%. Whether PD-L1 expression is predictive of benefit in SCLC must await 
analysis in a larger population.  
While over half of patients in this trial had two or more prior treatments, the 1-year survival rates, 31% and 42% for 
nivolumab-3 and nivolumab-1/ipilimumab-3, respectively, were comparable with or better than those reported in 
historical trials of second-line topotecan or amrubicin.
7,8,26
 Consistent with other trials with immune checkpoint 
inhibitors across multiple solid tumours, and unlike topotecan trials,
8
 this trial demonstrated a flattening of the 
overall survival curves for the nivolumab-3 and nivolumab-1/ipilimumab-3 cohorts, suggesting a survival benefit in 
a subset of patients.
9,10,12 
However, due to the small numbers in this trial, it is difficult to determine when this occurs. 
Also consistent with prior randomized trials of immuno-oncology agents, there appears to be more impact on overall 
survival than progression-free survival.  
Adverse events with nivolumab monotherapy and nivolumab plus ipilimumab were managed using established 
safety guidelines.
9,10,13,16
 Most toxicities in the nivolumab-3 and nivolumab-3/ipilimumab-1 cohorts were mild to 
moderate, with only four (4%) and four (7%) patients discontinuing because of toxicity, respectively. A higher rate 
of treatment-related grade 3 or 4 adverse events was seen in the nivolumab-1/ipilimumab-3 cohort (30% [18/61] vs 
13% [13/98] for nivolumab-3), with seven (11%) patients discontinuing because of toxicity. This regimen was used 
effectively and safely in a phase 3 trial in patients with melanoma, suggesting that this schedule is feasible in 
patients with SCLC.
16
 In all cohorts, fewer treatment-related toxicities were reported when compared with trials of 
topotecan or amrubicin.
7,8
 
Three patients had limbic encephalitis, and one patient receiving nivolumab plus ipilimumab died of myaesthenia 
gravis. Autoimmune encephalitis and myaesthenia gravis have been reported, albeit rarely, with both nivolumab and 
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ipilimumab.
9,31-36
 The frequency of these events seems to be higher in SCLC, perhaps due to the tendency for 
paraneoplastic neurological syndromes associated with this disease. Pneumonitis was reported in nine patients. It is 
critical to closely monitor for immune-related adverse events and/or unmasking of previously subclinical 
autoimmune disease processes, with prompt implementation of safety guidelines for effective management.  
On the basis of these encouraging phase 1/2 data, phase 3 studies for nivolumab (240 mg every 2 weeks) as a flat 
dose and nivolumab plus ipilimumab (1 mg/kg nivolumab and 3 mg/kg ipilimumab every 3 weeks for two 42-day 
cycles followed by nivolumab [240 mg every 2 weeks]) as maintenance therapy (in non-progressing patients) after 
first-line chemotherapy (CheckMate 451, NCT02538666), and for nivolumab (240 mg every 2 weeks) versus single 
agent chemotherapy as second-line therapy (CheckMate 331, NCT02481830) in SCLC were initiated and are 
currently ongoing. 
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Panel: Research in context (308 words) 
Evidence before this study 
We searched the scientific literature for outcomes following failure of first-line treatment in patients with small-cell 
lung cancer (SCLC) and available subsequent treatment options. The search terms “SCLC”, “recurrent”, “relapsed”, 
“second-line”, “third-line”, “phase 1”, “phase 2” and/or “phase 3” were used in PubMed focusing on reports and 
meta-analyses during the 10-year period prior to the start of the trial. To investigate the potential for immunotherapy 
in SCLC, the terms “SCLC” and “immune response”, “immunotherapy”, “PD-1”, “CTLA-4”, “NSCLC”, “PD-L1”, 
“nivolumab”, “ipilimumab”, “MK3475”, “lambrolizumab”, “MPDL3280A”, “MEDI4736”, and “tremelimumab” 
were used to search PubMed, congress abstracts from the annual meetings of the American Association of Cancer 
Research, American Society of Clinical Oncology, European Cancer Congress, and World Conference on Lung 
Cancer, and for ongoing trials in Clinicaltrials.gov. 
The searches revealed poor survival outcomes for patients with recurrent/relapsed SCLC and no treatment options 
beyond second line. The following pieces of evidence underscored the rationale for investigating nivolumab and 
nivolumab plus ipilimumab in SCLC: SCLC is immunogenic, ipilimumab in combination with chemotherapy was 
active in extensive disease-SCLC, and nivolumab and nivolumab plus ipilimumab showed encouraging activity in 
non-small cell lung cancer in phase 1/2 trials.  
Added value of this study 
Nivolumab alone and in combination with ipilimumab demonstrated durable objective responses, encouraging 
survival, and manageable safety in patients with advanced SCLC who had progressed after one or more prior 
regimens. To our knowledge, this is the first trial showing activity of nivolumab and nivolumab plus ipilimumab in 
SCLC, in a hard-to-treat population of patients with limited treatment options.  
Implications of all the available evidence 
Based on the notable rates and duration of responses and the median overall survival seen with nivolumab plus 
ipilimumab treatment in this patient population, phase 3 studies for nivolumab and nivolumab plus ipilimumab as 
maintenance therapy (in non-progressing patients) after first-line chemotherapy (CheckMate 451, NCT02538666), 
and for nivolumab versus chemotherapy as second-line therapy (CheckMate 331, NCT02481830) in SCLC are 
ongoing.
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TABLES AND FIGURES 
Table 1: Baseline patient characteristics*   
Data presented as n, n (%), or median (IQR) unless otherwise stated. IQR=interquartile range. PD-L1=programmed 
death-ligand 1. *No formal between-group comparison of incidence was performed for the baseline characteristics. 
†Three patients in the nivolumab-3 arm, two patients in the nivolumab-1/ipilimumab-3 arm, and four patients in the 
nivolumab-3/ipilimumab-1 arm did not receive first-line platinum therapy and did not meet eligibility criteria.
 
‡
Defined as a patient who relapsed <90 days after chemotherapy.
 §Percentage of PD-L1 evaluable patients; may 
exceed 100% due to rounding.  
 
 
 
 
Nivolumab-3  
(n=98) 
Nivolumab-1/ 
ipilimumab-3 
(n=61) 
Nivolumab-3/ 
ipilimumab-1 
(n=54) 
Median age, years  62·5 (57·0–68·0) 66·0 (58·0–71·0) 61·0 (56·0–65·0) 
Age ≥75 years                   9 (9%) 7 (11%) 0 
Male sex 61 (62%) 35 (57%) 32 (59%) 
Race    
White 91 (93%) 60 (98%) 52 (96%) 
Black/African American 3 (3%) 1 (2%) 0 
Other  4 (4%) 0 1 (2%) 
Not reported  0 0 1 (2%) 
Prior treatment regimens    
1 40 (41%) 32 (52%) 23 (43%) 
2–3 55 (56%) 23 (38%) 28 (52%) 
>3 3 (3%) 6 (10%) 3 (6%) 
First-line platinum-treated patients†    
Platinum-sensitive 55 (56%) 25 (41%) 21 (39%) 
Platinum-resistant‡ 30 (31%) 23 (38%) 21 (39%) 
Unknown 10 (10%) 11 (18%) 8 (15%) 
Smoking status    
Current/former smoker 95 (97%) 57 (93%) 48 (89%) 
Never smoked 3 (3%) 4 (7%) 5 (9%) 
Unknown 0 0 1 (2%) 
PD-L1 expression level,§    
≥1% 10 (14%) 9 (24%) 5 (13%) 
<1% 59 (86%) 28 (76%) 35 (88%) 
≥5% 4 (6%) 2 (5%) 1 (3%) 
<5% 65 (94%) 35 (95%) 39 (98%) 
Indeterminate/not evaluable/ 
missing 
29 (30%) 24 (39%) 14 (26%) 
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Table 2: Tumour response*  
 
Nivolumab-3  
(n=98) 
Nivolumab-1/ 
ipilimumab-3 
(n=61) 
Nivolumab-3/ 
ipilimumab-1 
(n=54) 
Objective response rate 10 (10%) 14 (23%) 10 (19%) 
(95% CI) (5–18) (13–36) (9–31) 
Best overall response    
Complete response 0 1 (2%) 0 
Partial response 10 (10%) 13 (21%) 10 (19%) 
Stable disease 22 (22%) 13 (21%) 9 (17%) 
Progressive disease 52 (53%) 23 (38%) 29 (54%) 
Unable to determine† 12 (12%) 8 (13%) 6 (11%) 
Not reported 2 (2%) 3 (5%) 0 
Time to objective response (IQR), months‡ 2·0 (1·3–2·8) 2·1 (1·4–2·8) 1·4 (1·3–2·7) 
Median duration of response (95% CI), 
months‡ 
NR (4·4–NR) 7·7 (4·0–NR) 4·4 (3·7–NR) 
    
Data presented as n or n (%) unless otherwise stated. IQR=interquartile range; NR=not reached. *All patients were 
enrolled at least 90 days prior to database lock. †In the nivolumab-3 cohort, seven patients died prior to disease 
assessment, four patients discontinued early (one due to toxicity, three due to clinical progression), and one patient 
withdrew consent prior to completing protocol; in the nivolumab-1/ipilimumab-3 cohort, five patients died prior to 
disease assessment, one patient discontinued early due to clinical progression, one patient was not evaluable as first 
assessment was not performed, and one patient withdrew consent for scans and follow-up visits; in the nivolumab-
3/ipilimumab-1 cohort, two patients died prior to disease assessment, three patients discontinued early (two due to 
clinical progression and one due to toxicity), and CT scan was not performed on one patient. ‡The analysis used data 
from all patients who had a response (10, 14, and 10 patients, respectively, in the nivolumab-3, nivolumab-
1/ipilimumab-3, and nivolumab-3/ipilimumab-1 groups).  
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Table 3: Treatment-related adverse events of any grade reported in ≥10% of patients in any treatment cohort* 
Event Nivolumab-3  
(n=98) 
Nivolumab-1/ipilimumab-3 
(n=61) 
Nivolumab-3/ipilimumab-1 
(n=54) 
 
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4 
Any event 39 (40%) 9 (9%)      4 (4%) 30 (49%) 14 (23%) 4 (7%) 30 (56%) 8 (15%) 2 (4%) 
Fatigue 10 (10%) 1 (1%) 0 16 (26%) 0 0 12 (22%) 0 0 
Pruritus 11 (11%) 0 0 11 (18%) 1 (2%) 0 5 (9%) 0 0 
Diarrhoea 7 (7%) 0 0 10 (16%) 3 (5%) 0 8 (15%) 1 (2%) 0 
Nausea 7 (7%) 0 0 6 (10%) 1 (2%) 0 4 (7%) 0 0 
Decreased appetite 6 (6%) 0 0 4 (7%) 0 0 6 (11%) 0 0 
Pneumonitis 2 (2%) 1 (1%) 0 1 (2%) 1 (2%) 0 2 (4%) 0 1 (2%) 
Vomiting 2 (2%) 1 (1%) 0 2 (3%) 1 (2%) 0 5 (9%) 0 0 
Hypothyroidism 3 (3%) 0 0 9 (15%) 1 (2%) 0 4 (7%) 0 0 
Increased aspartate 
aminotransferase 
3 (3%) 0 0 3 (5%) 0 0 0 1 (2%) 0 
Hyperthyroidism 2 (2%) 0 0 7 (11%) 0 0 3 (6%) 0 0 
Hyponatraemia 2 (2%) 0 0 0 1 (2%) 0 0 0 0 
Increased alanine 
aminotransferase 
2 (2%) 1 (1%) 0 2 (3%) 0 0 0 1 (2%) 0 
Increased transaminases 2 (2%) 0 0 0 0 0 1 (2%) 1 (2%) 0 
Rash 2 (2%) 0 0 10 (16%) 2 (3%) 0 4 (7%) 0 0 
Anaemia 1 (1%) 0 0 4 (7%) 0 0 3 (6%) 1 (2%) 0 
Dyspnoea 1 (1%) 0 0 0 1 (2%) 0 1 (2%) 2 (4%) 0 
Rash, maculopapular 1 (1%) 0 0 6 (10%) 2 (3%) 0 2 (4%) 0 0 
Adrenal insufficiency 0 0 0 1 (2%) 0 0 1 (2%) 1 (2%) 0 
Aseptic meningitis 0 0 0 0 0 0 0 0 1 (2%) 
Cardiomyopathy 0 0 0 0 0 1 (2%) 0 0 0 
Colitis 0 0 0 1 (2%) 1 (2%) 0 0 1 (2%) 0 
Decreased neutrophil 
count 
0 0 0 0 1 (2%) 0 0 0 0 
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Drug-induced liver injury 0 1 (1%) 0 0 0 0 0 0 0 
Encephalitis 0 0 1 (1%) 1 (2%) 0 0 0 0 0 
Eyelid ptosis 0 0 0 0 1 (2%) 0 0 0 0 
Haemorrhagic gastritis 0 0 0 0 1 (2%) 0 0 0 0 
Hyperglycaemia 0 0 1 (1%) 2 (3%) 0 1 (2%) 0 0 0 
Hypertransaminasaemia 0 0 0 0 1 (2%) 0 0 0 0 
Hypoxia 0 1 (1%) 0 0 0 0 0 0 0 
Ileus 0 0 0 0 0 0 0 1 (2%) 0 
Increased amylase 0 0 1 (1%) 3 (5%) 1 (2%) 0 2 (4%) 0 0 
Increased gamma 
glutamyltransferase 
0 0 1 (1%) 0 0 0 0 1 (2%) 0 
Increased lipase 0 0 0 2 (3%) 4 (7%) 1 (2%) 0 0 0 
Large intestine perforation 0 0 0 0 0 0 0 1 (2%) 0 
Myaesthenia gravis 0 0 0 0 1 (2%) 0 0 0 0 
Non-cardiac chest pain 0 1 (1%) 0 0 0 0 0 0 0 
Pericardial effusion 0 1 (1%) 0 0 0 0 0 0 0 
Peripheral neuropathy 0 0 0 0 0 0 0 1 (2%) 0 
Renal failure 0 0 0 0 0 1 (2%) 0 0 0 
Stomatitis  0 1 (1%) 0 1 (2%) 0 0 0 0 0 
Thrombocytopenia 0 0 0 0 0 0 3 (6%) 1 (2%) 0 
Tumour lysis syndrome 0 0 0 0 0 0 0 1 (2%) 0 
   
Data presented as n or n (%). *Safety analyses included all patients who were enrolled at least 90 days prior to database lock; patients with adverse events after 
crossover from nivolumab monotherapy to combination treatment are excluded. Some patients had more than one adverse event. One patient in the nivolumab-
1/ipilimumab-3 treatment cohort died from myaesthenia gravis considered treatment-related. This table reports any-grade treatment-related events in ≥10% of 
patients and all grade 3–4 events. No treatment-related grade 5 events were reported. All causality adverse events and serious adverse events are listed in pages 
25–28, appendix. 
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Figure Legends 
Figure 1: Study design 
 
Footnote to Figure 1:  *Nivolumab 1 mg/kg plus ipilimumab 1 mg/kg: first patient enrolled November 20, 2013; last patient enrolled December 19, 2013. 
†Nivolumab monotherapy: first patient enrolled November 18, 2013; last patient enrolled July 28, 2015. 
‡
Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg: first 
patient enrolled February 3, 2014; last patient enrolled July 17, 2015. 
§
Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg: first patient enrolled October 20, 2014; 
last patient enrolled April 9, 2015. Data are based on a November 6, 2015 database lock. DOR=duration of response. IV=intravenous. ORR=objective response 
rate. OS=overall survival. PD-L1=programmed death ligand 1. PFS=progression-free survival. Q2W=every 2 weeks. Q3W=every 3 weeks. RECIST=Response 
Evaluation Criteria In Solid Tumors. SCLC=small cell lung cancer. 
 
Figure 2: Changes in tumour burden in individual patients treated in all lines 
 
Only patients with target lesions at baseline and with at least one on-treatment tumour assessment were included (nivolumab-3, n = 80; nivolumab-1/ipilimumab-
3, n = 46; nivolumab-3/ipilimumab-1, n = 47). Shown is the tumour burden (assessed as the longest linear dimension) over time in patients receiving nivolumab-
3 (A), nivolumab-1/ipilimumab-3 (B), and nivolumab-3/ipilimumab-1 (C). Horizontal reference line indicates the 30% reduction consistent with a Response 
Evaluation Criteria in Solid Tumours (RECIST), version 1·1, objective response. Tumour regression followed both conventional and immune-related patterns of 
response, such as a prolonged reduction in the tumour burden in the presence of new lesions. CR=complete response. PR=partial response. 
 
Figure 3: Kaplan-Meier curves of overall survival and progression-free survival in all patients 
Panels show the Kaplan-Meier curves for overall survival (A) and progression-free survival (B). Symbols indicate censored observations, and the horizontal line 
indicates the rates of survival at 1 year. NR = not reached. 
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Supplemental Text
List of Investigators 
Finland: Petri Bono (Cancer Center, Helsinki University Hospital and University of Helsinki); Germany: Akin 
Atmaca (Krankenhaus Nordwest UCT- University Cancer Center, Frankfurt), Dirk Jäger (Nationales Centrum für 
Tumorerkrankungen [NCT], University Medical Center, Heidelberg); Italy: Paolo A Ascierto (Istituto Nazionale 
Tumori Fondazione Pascale), Filippo de Braud (Fondazione IRCCS Istituto Nazionale dei Tumori Milano); Spain:
Emiliano Calvo (START Madrid, Centro Integral Oncológico Clara Campa), José A López-Martin, MD (Hospital 
Universitario 12 de Octubre), Victor Moreno (START-Madrid-FJD), Noemi Reguart (Hospital Clínic de Barcelona); 
United Kingdom: Ian Chau (Royal Marsden Hospital), Jeffry Evans (University of Glasgow); United States: Asim 
Amin (Levine Cancer Institute, Carolinas Medical Center), Scott J Antonia (H. Lee Moffitt Cancer Center & 
Research Institute), Johanna Bendell (Sarah Cannon Research Institute/Tennessee Oncology, PLLC), Joseph Paul 
Eder (Yale Comprehensive Cancer Center), Leora Horn (Vanderbilt-Ingram Cancer Center), Dung T Le (The 
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University), Michael A Morse (Duke University 
Medical Center), Patrick A Ott (Dana-Farber Cancer Institute), M Catherine Pietanza (Memorial Sloan Kettering 
Cancer Center, Weill Cornell Medical College), Rathi N Pillai (Winship Cancer Institute of Emory University), 
Padmanee Sharma (The University of Texas M.D. Anderson Cancer Center), Matthew Taylor (Oregon Health & 
Science University)
Criteria for dose delays and treatment discontinuation 
The criteria for dose delay of nivolumab, ipilimumab, or both include the following treatment-related adverse events: 
grade ≥2 non-skin event (except for grade 2 fatigue), grade 3 skin, grade 3 laboratory abnormality (except for 
asymptomatic amylase and lipase). If the patient has normal baseline aspartate aminotransferase (AST), normal 
alanine aminotransferase (ALT) or normal total bilirubin levels, the dose will be delayed for grade 2 toxicity or 
greater. If baseline is grade 1 for these laboratory parameters, dose will be delayed for grade 3 toxicity or greater.  
Criteria for permanent treatment discontinuation include the following treatment-related adverse events: grade 2 
uveitis, grade 3 non-skin events lasting >7 days, grade 3 laboratory abnormalities of thrombocytopenia or liver 
function test, and all grade 4 events as well as laboratory abnormalities except for asymptomatic amylase or lipase 
elevations.  
Case details: patient who died of treatment-related myaesthenia gravis in the nivolumab-1/ipilimumab-3 
cohort 
The patient was a 70-year-old male with a 1-year history of stage 4 SCLC, which was refractory to 
platinum/etoposide and radiation. The patient presented with ptosis and diplopia 16 days after starting treatment, and 
was hospitalised. He tested positive for acetylcholine receptor-modulating and striational antibodies. Nivolumab-
1/ipilimumab-3 treatment was discontinued, and the patient was treated with prednisone, underwent three sessions 
of plasmapheresis, and was discharged 7 days later. The patient was readmitted 1 day later with dyspnoea and 
weakness, required intubation, and did not improve, despite treatment with steroids, plasmapheresis, or intravenous 
immunoglobulin. Complications with complete heart block, sepsis, and bleeding duodenal ulcers ensued, and 
medical care was withdrawn on day 22. 
Treatment-related adverse events of grade 2 or higher in patients who crossed over from nivolumab 
monotherapy to nivolumab plus ipilimumab combination therapy 
Treatment-related adverse events of grade 2 or higher occurred in three of nine patients who crossed over from 
nivolumab monotherapy to nivolumab plus ipilimumab combination therapy. One patient who crossed over to 
nivolumab-1/ipilimumab-3 treatment experienced grade 3 elevations in alanine aminotransferase levels and grade 2 
elevations in aspartate aminotransferase and alkaline phosphatase levels. One patient who crossed over to 
nivolumab-3/ipilimumab-1 treatment experienced a grade 2 infusion-related reaction. One patient who crossed over 
to nivolumab-3/ipilimumab-1 treatment experienced a grade 2 maculopapular rash.  
4 
Figure S1: Kaplan-Meier curves of overall survival for patients with one prior therapy and patients with two 
or more prior therapies 
Panels show the Kaplan-Meier curves for overall survival in patients with one prior therapy (A) and patients with 
two or more prior therapies (B). Symbols indicate censored observations, and the horizontal line indicates the rates 
of overall survival at 1 year (panel A only). CR=complete response; NA=not applicable; PR=partial response. 
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Figure S2: Kaplan-Meier curves of progression-free survival in patients with one prior therapy and patients 
with two or more prior therapies 
Panels show the Kaplan-Meier curves for progression-free survival in all patients (A), patients with one prior 
therapy (B), and patients with two or more prior therapies (C). Symbols indicate censored observations, and 
horizontal lines indicate the rates of progression-free survival at 1 year.  
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Figure S3: Changes in tumour burden according to platinum sensitivity in individual patients treated in 
second line  
Only patients with target lesions at baseline and with ≥1 on-treatment tumour assessment were included (nivolumab-
3, n=31; nivolumab-1/ipilimumab-3, n=21; nivolumab-3/ipilimumab-1, n=17). Panels show the tumour burden 
(assessed as the longest linear dimension) over time in patients receiving second-line nivolumab-3 (A), nivolumab-
1/ipilimumab-3 (B), and nivolumab-3/ipilimumab-1 (C). Horizontal reference line indicates the 30% reduction 
consistent with a Response Evaluation Criteria in Solid Tumors (RECIST), version 1·1, objective response. 
CR=complete response; PR=partial response. 
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Figure S3: Changes in tumour burden according to platinum sensitivity in individual patients treated in second line 
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Figure S4: Changes in tumour burden according to tumour PD-L1 expression status 
Only patients with target lesions at baseline and with ≥1 on-treatment tumour assessment were included (nivolumab-
3, n=76; nivolumab-1/ipilimumab-3, n=46; nivolumab-3/ipilimumab-1, n=47). Panels show the maximum change 
from baseline in the target lesion according to tumour programmed death-ligand 1 (PD-L1) expression status using a 
1% cut-off in patients receiving nivolumab-3 (A), nivolumab-1/ipilimumab-3 (B), and nivolumab-3/ipilimumab-1 
(C). Assessments after progression or start of subsequent anticancer therapy are excluded. Negative/positive value 
means maximum tumour reduction/minimum tumour increase. Sixty-seven patient samples were indeterminate, 
nonevaluable, or missing. Horizontal reference lines indicate the 30% reduction consistent with a RECIST, version 
1·1, response. The change in tumour burden was defined as the percentage decrease in the sum of the reference 
diameters of the target lesion from baseline to nadir, observed up to the date of progression (as assessed by the 
investigator per RECIST, version 1·1), subsequent anticancer therapy, or death. PD-L1=programmed death-ligand 1. 
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Figure S4: Changes in tumour burden according to tumour PD-L1 expression status
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Table S1: Enrolment by country and site 
Site - 
country 
Site 
number Principle investigator Site - Institution 
Number of patients 
treated 
N = 216* 
Spain 0017 Lopez-Martin, Jose A Hospital Universitario 12 de Octubre 28 
United 
States 0021 Antonia, Scott J H. Lee Moffitt Cancer Center & Research Institute 23 
United 
States 0011 Bendell, Johanna Sarah Cannon Research Institute/Tennessee Oncology 21 
Spain 0010 Calvo, Emiliano START Madrid, Centro Integral Oncológico Clara Campal 18 
United 
States 0005 Ott, Patrick A Dana-Farber Cancer Institute 15 
United 
States 0007 Taylor, Matthew Oregon Health & Science University 15 
United 
States 0015 Eder, Joseph Paul Yale Comprehensive Cancer Center 13 
Germany 0016 Jaeger, Dirk Nationales Centrum für Tumorerkrankungen (NCT), University Medical Center 13 
United 
States 0006 Pietanza, M. Catherine Memorial Sloan Kettering Cancer Center 10 
Italy 0019 De Braud, Filippo Fondazione IRCCS Istituto Nazionale dei Tumori Milano 8 
United 
States 0004 Le, Dung T 
The Sidney Kimmel Comprehensive Cancer Center at Johns 
Hopkins University 8 
United 
States 0008 Morse, Michael A Duke University Medical Center 8 
Italy 0020 Ascierto, Paolo A Istituto Nazionale Tumori Fondazione Pascale 7 
United 
States 0003 Amin, Asim Levine Cancer Institute, Carolinas Medical Center 6 
United 
States 0002 Horn, Leora Vanderbilt-Ingram Cancer Center 6 
United 
Kingdom 0012 Evans, Jeff Beatson West Of Scotland Cancer Centre 5 
United 
States 0001 Pillai, Rathi Winship Cancer Institute of Emory University 5 
Germany 0026 Atmaca, Akin Krankenhaus Nordwest UCT-University Cancer Center 2 
Finland 0014 Bono, Petri Comprehensive Cancer Center, Helsinki University Hospital 2 
United 
Kingdom 0013 Chau, Ian Royal Marsden Hospital 2 
United 
States 0009 Sharma, Padmanee The University of Texas M.D. Anderson Cancer Center 1 
*Enrolment numbers are based on the November 6, 2015 database lock. 
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Table S2: On-study safety assessment schedules in nivolumab and nivolumab/ipilimumab cohorts* 
Safety assessment Timing considerations Nivolumab monotherapy Nivolumab/ipilimumab week 1 
to week 12 
Nivolumab/ipilimumab 
week 13 onward 
Day 1 
Week 1, 3, 5, 7, 9, etc 
Day 1 
Week 1, 4, 7, 10 
Day 1 
Week 13, 15, 17, 19, 21, etc 
Targeted physical examination 72 hours prior to dosing X X (+day 4, week 2,5) X 
Vital signs and oxygen  saturation 72 hours prior to dosing X X (+day 4, week 2,5) X 
Physical measurements  Weight prior to dosing X X (+day 4, week 2,5) X 
Adverse events assessment continuously continuously continuously 
Review of concomitant medications continuously continuously continuously 
Laboratory tests* 72 hours prior to dosing X X (+day 4, week 2,5) X 
Pregnancy test 24 hours prior to dosing, 
for WOCBP only 
X 
(baseline and every 4 weeks) 
X 
(baseline and every 3 weeks) 
X 
(baseline and every 4 weeks) 
*Complete blood count with differential, liver function tests, blood urea nitrogen or serum urea level, creatinine, albumin, calcium, magnesium, sodium, 
potassium, chloride, lactic acid dehydrogenase, glucose, amylase, lipase, and thyroid stimulating hormone. WOCBP=women of child-bearing potential. 
X=assessment to be performed. 
20 
Table S3: Patient baseline characteristics in the nivolumab-1/ipilimumab-1 cohort
Baseline characteristics Nivolumab-1/ipilimumab-1 (n=3) 
Median age (IQR), years 
Age ≥75 
61 (52–65) 
0 
Male sex 2 (67%) 
Race 
White 
Black/African American 
Other 
2 (67%) 
1 (33%) 
0 
Prior treatment regimens  
1 
2–3 
>3 
1 (33%) 
2 (67%) 
0 
Sensitivity to first-line platinum treatment  
Platinum sensitive 
Platinum resistant 
Unknown 
1 (33%) 
0 
2 (67%) 
Current/former smoker  3 (100%) 
PD-L1 expression level* 
≥1% 
<1% 
≥5% 
<5% 
Indeterminant/not evaluable/missing 
1 (50%) 
1 (50%) 
0 
2 (100%) 
1 (33%) 
Data presented as n or n (%), unless otherwise stated. All patients were enrolled at least 90 days prior to database 
lock. PD-L1=programmed death-ligand 1. *Percentage of PD-L1 evaluable patients.  
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Table S4: Tumour response in the nivolumab-1/ipilimumab-1 cohort 
Nivolumab-1/ipilimumab-1 
(n=3)
Objective response rate 
(95% CI) 
1 (33%) 
(0·8–91) 
Best overall response 
Complete response 
Partial response 
Stable disease 
Progressive disease 
1 (33%) 
0 
2 (67%) 
0 
Time to objective response (IQR), months* 2·7 (2·7 – 2·7) 
Median duration of response (95% CI), months* NR  
Data presented as n, or n (%) unless otherwise stated. All patients were enrolled at least 90 days prior to database 
lock. IQR=interquartile range. NR=not reached. *The analysis used data from the one patient who had a response. 
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Table S5: Treatment-related adverse events in the nivolumab-1/ipilimumab-1 cohort 
Event Nivolumab-1/ipilimumab-1 
(n=3) 
Grade 1-2      Grade 3  Grade 4 
Total number of patients with an event 2 (67%) 0 0 
Fatigue 2 (67%) 0 0 
Diarrhoea 2 (67%) 0 0 
Abdominal pain 1 (33%) 0 0 
Arthralgia 1 (33%) 0 0 
Colitis 1 (33%) 0 0 
Decreased appetite 1 (33%) 0 0 
Dyspnoea 1 (33%) 0 0 
Lacrimation increased 1 (33%) 0 0 
Nausea 1 (33%) 0 0 
Peripheral sensory neuropathy 1 (33%) 0 0 
Pruritus 1 (33%) 0 0 
Thyroiditis 1 (33%) 0 0 
Vision blurred 1 (33%) 0 0 
Treatment-related adverse events leading to 
discontinuation* 0 0 
0 
Data presented as n (%). Safety analyses include all patients who were enrolled at least 90 days prior to database 
lock. Some patients had more than one adverse event. *At the time of database lock, two patients had discontinued 
treatment; one due to disease progression, one due to an adverse event unrelated to study drug. 
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Table S6: Treatment exposure and patient disposition  
Nivolumab-3   
(n=98) 
Nivolumab-1/ 
ipilimumab-3  
(n=61) 
Nivolumab-3/ipilimumab-1 
(n=54) 
Median number of infusions  
Nivolumab 3·5 (2·0–6·0) 3·0 (2·0–14·0) 2·0 (2·0–6·0) 
Ipilimumab NA 3·0 (2·0–4·0) 2·0 (2·0–4·0) 
Median follow-up, days* 198·5 (163·0–464·0) 361·0 (273·0–470·0) 260·5 (248·0–288·0) 
Patients continuing treatment 21 (21%) 19 (31%) 11 (20%) 
Patients not continuing treatment 77 (79%) 42 (69%) 43 (80%) 
Progressive disease 57 (58%) 26 (43%) 36 (67%) 
AE related to study drug 4 (4%) 7 (11%) 4 (7%)
AE unrelated to study drug 10 (10%) 5 (8%) 1 (2%) 
Death 0 2 (3%) 0 
Patient request/withdrew consent 5 (5%) 1 (2%) 2 (4%) 
Other 1(1%) 1 (2%) 0 
Patients continuing to be followed† 66 (67%) 48 (79%) 44 (82%) 
Deaths 48 (49%) 30 (49%) 25 (46%) 
Data presented as n,n (%) or median (IQR) unless otherwise stated. All patients were enrolled at least 90 days prior 
to database lock. AE=adverse event. IQR=interquartile range NA=not applicable. *Patients continuing in the study 
at the time of database lock. †Includes patients still on treatment and patients off treatment continuing in the follow-
up period. 
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Table S7: Best overall tumour response by lines of therapy
One prior therapy Two or more prior therapies
Nivolumab-3
(n=40)
Nivolumab-1/
ipilimumab-3
(n=32)
Nivolumab-3/
ipilimumab-1
(n=23) 
Nivolumab-3  
(n=58)
Nivolumab-1/
ipilimumab-3
(n=29)
Nivolumab-3/
ipilimumab-1
(n=31) 
Objective response rate § 
(95% CI) 
4 (10%) 
(3–24) 
9 (28%) 
(14–47) 
5 (22%) 
(8–44) 
6 (10%) 
(4–21) 
5 (17%) 
(6–36) 
5 (16%) 
(6–34) 
Best overall response ¶  
Complete response 
Partial response 
Stable disease 
Progressive disease 
Unable to determine 
Not reported 
0 
4 (10%) 
8 (20%) 
22 (55%) 
5 (13%) 
1 (3%) 
1 (3%) 
8 (25%) 
6 (19%) 
10 (31%) 
6 (19%) 
1 (3%) 
0 
5 (22%) 
3 (13%) 
12 (52%) 
3 (13%) 
0 
0 
6 (10%) 
14 (24%) 
30 (52%) 
7 (12%) 
1 (2%) 
0  
5 (17%) 
7 (24%) 
13 (45%) 
2 (7%) 
2 (7%) 
0 
5 (16%) 
6 (19%) 
17 (55%) 
3 (10%) 
0 
Data presented as n or n (%) unless otherwise stated. All patients were enrolled at least 90 days prior to database lock. 
Table S8: Best overall tumour response by sensitivity to first-line platinum-based treatment
Platinum sensitive* Platinum resistant†
Nivolumab-3
(n=55)
Nivolumab-1/
ipilimumab-3
(n=25)
Nivolumab-3/
ipilimumab-1
(n=21) 
Nivolumab-3  
(n=30)
Nivolumab-1/
ipilimumab-3
(n=23)
Nivolumab-3/
ipilimumab-1
(n=21) 
Objective response rate 
(95% CI) 
6 (11%) 
(4–22) 
7 (28%) 
(12–49) 
4 (19%) 
(5–42) 
3 (10%) 
(2–27) 
4 (17%) 
(5–39) 
2 (10%) 
(1–30) 
Best overall response  
Complete response 
Partial response 
Stable disease 
Progressive disease 
Unable to determine 
Not reported 
0 
6 (11%) 
14 (25%) 
29 (53%) 
5 (9%) 
1 (2%) 
0 
7 (28%) 
7 (28%) 
8 (32%) 
3 (12%) 
0 
0 
4 (19%) 
5 (24%) 
11 (52%) 
1 (5%) 
0 
0 
3 (10%) 
5 (17%) 
16 (53%) 
5 (17%) 
1 (3%) 
1 (4%) 
3 (13%) 
2 (9%) 
10 (44%) 
5 (22%) 
2 (9%) 
0 
2 (10%) 
1 (5%) 
13 (62%) 
5 (24%) 
0 
Data presented as n (%) unless otherwise stated. All patients were enrolled at least 90 days prior to database lock. For patients with known response to platinum-
based therapy, platinum sensitivity was unknown for 29 patients as follows: nivolumab-3, n=10; nivolumab-1/ipilimumab-3, n=11; nivolumab-3/ipilimumab-1, 
n=8. *Patient relapsed ≥90 days after platinum-based chemotherapy. †Patient failed to respond to, or relapsed <90 days after, platinum-based chemotherapy.  
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Table S9: All-causality adverse events by category reported in ≥10% of patients in any treatment cohort
Category Nivolumab-3 
(n=98)
Nivolumab-1/ipilimumab-3
(n=61)
Nivolumab-3/ipilimumab-1
(n=54)
Any grade      Grade 3 or 4 Any grade     Grade 3 or 4 Any grade     Grade 3 or 4 
Total number of patients with an 
event 95 (96%) 21 (21%) 61 (100%) 30 (49%) 53 (98%) 15 (28%) 
Gastrointestinal disorders 59 (60%) 9 (9%) 40 (66%) 9 (15%) 33 (61%) 4 (7%) 
General disorders and    
administration site conditions 55 (56%) 5 (5%) 42 (69%) 5 (8%) 37 (69%) 4 (7%) 
Metabolism and nutritional 
disorders 47 (48%) 15 (15%) 32 (52%) 10 (16%) 22 (41%) 3 (6%) 
Respiratory, thoracic and 
mediastinal disorders 42 (43%) 11 (11%) 25 (41%) 6 (10%) 28 (52%) 7 (13%) 
Infections and infestations 27 (28%) 6 (6%) 21 (34%) 7 (11%) 20 (37%) 5 (9%) 
Investigations 26 (27%) 12 (12%) 29 (48%) 12 (20%) 16 (30%) 2 (4%) 
Nervous system disorders 26 (27%) 3 (3%) 21 (34%) 6 (10%) 19 (35%) 3 (6%) 
Musculoskeletal and connective 
tissue disorders 21 (21%) 2 (2%) 16 (26%) 0 18 (33%) 1 (2%) 
Skin and subcutaneous tissue 
disorders 21 (21%) 0 31 (51%) 4 (7%) 20 (37%) 0 
Blood and lymphatic system 
disorders 19 (19%) 1 (1%) 11 (18%) 3 (5%) 13 (24%) 5 (9%) 
Injury, poisoning, and procedural 
complications 14 (14%) 2 (2%) 7 (11%) 2 (3%) 5 (9%) 0 
Psychiatric disorders 11 (11%) 3 (3%) 15 (25%) 1 (2%) 10 (19%) 1 (2%) 
Cardiac disorders 10 (10%) 4 (4%) 9 (15%) 6 (10%) 5 (9%) 2 (4%) 
Endocrine disorders 9 (9%) 0 16 (26%) 1 (2%) 10 (19%) 1 (2%) 
Eye disorders 5 (5%) 0 5 (8%) 1 (2%) 5 (9%) 0 
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Data presented as n (%). Safety analyses included all patients who were enrolled at least 90 days prior to database lock; nivolumab-1/ipilimumab-1 cohort is 
excluded; patients with adverse events after crossover from nivolumab monotherapy to combination treatment are excluded. Some patients had more than one 
adverse event. Grade 5 events (deaths) occurred in 36 (37%), 16 (26%), and 14 (26%) patients in the nivolumab-3, nivolumab-1/ipilimumab-3, and nivolumab-
3/ipilimumab-1 cohorts, respectively. One patient in the nivolumab-1/ipilimumab-3 treatment cohort died from myaesthenia gravis that was considered 
treatment-related; there were no other treatment-related deaths.  
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Table S10: All-causality serious adverse events reported by category
Category Nivolumab-3 
(n=98) 
Nivolumab-1/ipilimumab-3
(n=61)
Nivolumab-3/ipilimumab-1
(n=54)
Grade 
1–2      Grade 3  Grade 4 Grade 5 
Grade 
1–2      Grade 3  Grade 4 Grade 5 Grade 1–2 Grade 3  Grade 4 Grade 5 
Total number of 
patients with an 
event 
8 (8%) 13 (13%) 4 (4%) 36 (37%) 3 (5%) 14 (23%) 6 (10%) 16 (26%) 10 (19%) 9 (17%) 3 (6%) 14 (26%) 
Neoplasms, benign, 
malignant, and 
unspecified 
1 (1%) 2 (2%) 1 (1%) 35 (36%) 0 0 0 14 (23%) 3 (6%) 0 1 (2%) 14 (26%) 
Respiratory, 
thoracic, and 
mediastinal 
disorders 
2 (2%) 9 (9%) 1 (1%) 0 2 (3%) 3 (5%) 1 (2%) 0 5 (9%) 3 (6%) 1 (2%) 0 
Gastrointestinal 
disorders 3 (3%) 6 (6%) 1 (1%) 0 1 (2%) 6 (10%) 0 0 3 (6%) 3 (6%) 0 0 
Infections and 
infestations 0 4 (4%) 1 (1%) 1 (1%) 2 (3%) 4 (7%) 2 (3%) 0 0 4 (7%) 1 (2%) 0 
Cardiac disorders 1 (1%) 2 (2%) 2 (2%) 1 (1%) 0 5 (8%) 1 (2%) 0 0 1 (2%) 0 0 
General disorders 
and administration 
site conditions 
5 (5%) 1 (1%) 0 0 1 (2%) 3 (5%) 0 2 (3%) 1 (2%) 3 (6%) 0 0 
Metabolism and 
nutrition disorders 0 4 (4%) 1 (1%) 0 1 (2%) 2 (3%) 2 (3%) 0 0 1 (2%) 0 0 
Injury, poisoning, 
and procedural 
complications 
3 (3%) 1 (1%) 0 0 0 1 (2%) 1 (2%) 0 0 0 0 0 
Investigations 0 3 (3%) 0 0 0 3 (5%) 0 0 0 1 (2%) 0 0 
Nervous system 
disorders 2 (2%) 1 (1%) 0 0 2 (3%) 4 (7%) 1 (2%) 0 2 (4%) 2 (4%) 0 0 
Musculoskeletal and 
connective tissue 
disorders 
0 2 (2%) 0 0 0 0 0 0 0 1 (2%) 0 0 
Psychiatric disorders 0 2 (2%) 0 0 1 (2%) 0 0 0 0 1 (2%) 0 0 
Vascular disorders 0 2 (2%) 0 0 1 (2%) 0 0 0 0 1 (2%) 0 0 
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Hepatobiliary 
disorders 1 (1%) 1 (1%) 0 0 0 1 (2%) 0 0 0 0 0 0 
Endocrine 
disorders 2 (2%) 0 0 0 1 (2%) 1 (2%) 0 0 0 1 (2%) 0 0 
Blood and lymphatic 
system disorders 0 1 (1%) 0 0 0 0 0 0 0 0 1 (2%) 0 
Ear and labyrinth 
disorders 1 (1%) 0 0 0 0 0 0 0 0 0 0 0 
Renal and urinary 
disorders 0 1 (1%) 0 0 0 0 1 (2%) 0 0 0 0 0 
Eye disorders 0 0 0 0 0 0 0 0 1 (2%) 0 0 0 
Data presented as n (%). Safety analyses included all patients who were enrolled at least 90 days prior to database lock; nivolumab-1/ipilimumab-1 cohort is 
excluded; patients with adverse events after crossover from nivolumab monotherapy to combination treatment are excluded. Some patients had more than one 
adverse event. One patient in the nivolumab-1/ipilimumab-3 treatment cohort died from myaesthenia gravis that was considered treatment-related; there were no 
other treatment-related deaths.
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Table S11: Treatment-related elevations in liver function tests
Event Nivolumab-3  
(n=98) 
Nivolumab-1/ipilimumab-3 
(n=61) 
Nivolumab-3/ipilimumab-1 
(n=54) 
Grade 1–2 Grade 3  Grade 4 Grade 1–2 Grade 3  Grade 4 Grade 1–2 Grade 3  Grade 4 
Increased alanine 
aminotransferase 2 (2%) 1 (1%)* 0 2 (3%) 0 0 0 1 (2%) 0 
Increased aspartate 
aminotransferase 3 (3%) 0 0 3 (5%) 0 0 0 1 (2%) 0 
Increased blood alkaline 
phosphatase 2 (2%) 0 0 2 (3%) 0 0 0 0 0 
Increased transaminases 2 (2%) 0 0 0 0 0 1 (2%) 1 (2%) 0 
Increased gamma 
glutamyltransferase 0 0 1 (1%)* 0 0 0 0 1 (2%) 0 
Data presented as n (%). Safety analyses included all patients who were enrolled at least 90 days prior to database lock; patients with adverse events after 
crossover from nivolumab monotherapy to combination treatment are excluded. Some patients had more than one adverse event. *Patient discontinued treatment. 
